Aspira Pathlab & Diagnostics Ltd. Corporate Filings & Announcements

Latest corporate announcements and filings from Aspira Pathlab & Diagnostics Ltd. on BSE

Search Inside the pdf :

Aspira Pathlab & Diagnostics Ltd.

07 May 2025, 05:15PM

63.50

-0.67%

Board Meeting

Aspira Pathlab & Diagnostics Ltd - 540788 - Board Meeting Intimation for Approval Of Audited Standalone …

BSE India

Aspira Pathlab & Diagnostics Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2025 ,inter alia, to consider and approve Audited Standalone & Consolidated Financial Results of the Company alongwith the Auditor Report as on March 31, 2025 & to transact other businesses with the permission of Chair.

pdf

Aspira Pathlab & Diagnostics Ltd.

22 Apr 2025

63.50

-0.67%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Updation In Contact Details Of The Company Registrar …

BSE India

Updation in Contact Details of the Company Registrar and Share Transfer Agent

pdf

Aspira Pathlab & Diagnostics Ltd.

15 Apr 2025

63.50

-0.67%

Corp. Note

Aspira Pathlab & Diagnostics Ltd - 540788 - Format of the Annual Disclosure to be made …

BSE India

Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Company Aspira Pathlab & Diagnostics Ltd 2 CIN NO. L85100MH1973PLC289209 3 Report filed for FY 2024-2025 Details of the Current block (all figures in Rs crore): 4 2 - year block period (Specify financial years)* NA 5 Incremental borrowing done in FY (T)(a) 0.00 6 Mandatory borrowing to be done through debt securities in FY (T) (b) = (25% of a) 0.00 7 Actual borrowing done through debt securities in FY (T)(c) 0.00 8 Shortfall in the borrowing through debt securities, if any, for FY (T - 1) carried forward to FY (T) (d) 0 8Quantum of (d), which has been met from (c)(e)* 0 9 Shortfall, if any, in the mandatory borrowing through debt securities for FY (T) { after adjusting for any shortfall in borrowing for FY(T - 1) which was carried forward to FY(T)}(f) = (b) - [(c) - (e)]{ If the calculated value is zero or negative, write 'nil'}* 0 Details of penalty to be paid, if any, in respect to previous block (all figures in Rs crore): 2 - year Block period (Specify financial years)NA Amount of fine to be paid for the block, if applicable Fine = 0.2% of {(d) - (e)}#0.00 Name of the Company Secretary :-Krupali ShahDesignation :-Company Secretary Name of the Chief Financial Officer :- Balkrishna Talawadekar Designation : -Chief Financial Officer Date: 15/04/2025

pdf

Aspira Pathlab & Diagnostics Ltd.

15 Apr 2025

63.50

-0.67%

Corp. Note

Aspira Pathlab & Diagnostics Ltd - 540788 - Format of the Initial Disclosure to be made …

BSE India

Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAspira Pathlab & Diagnostics Ltd 2CIN NO.L85100MH1973PLC289209 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Krupali Shah Designation: Company Secretary EmailId: krupali.shah@aspiradiagnostics.com Name of the Chief Financial Officer: Balkrishna Talawadekar Designation: Chief Financial Officer EmailId: balkrishna.talawadekar@aspiradiagnostics.com Date: 15/04/2025 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.

pdf

Aspira Pathlab & Diagnostics Ltd.

09 Apr 2025

63.50

-0.67%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) …

BSE India

Compliance Certificate in accordance with regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2025

pdf

Aspira Pathlab & Diagnostics Ltd.

08 Apr 2025

63.50

-0.67%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Intimation Under Regulation 30 Of The SEBI (LODR) …

BSE India

Announcement as per regulation 30 of the SEBI (LODR) Regulations, 2015

pdf

Aspira Pathlab & Diagnostics Ltd.

26 Mar 2025

63.50

-0.67%

SAST

Aspira Pathlab & Diagnostics Ltd - 540788 - Closure of Trading Window

BSE India

Intimation of Closure of Trading Window for the quarter and year ended March 31, 2025

pdf

Aspira Pathlab & Diagnostics Ltd.

25 Mar 2025

63.50

-0.67%

Company Update

Aspira Pathlab & Diagnostics Ltd - 540788 - Announcement under Regulation 30 (LODR)-Code of Conduct under …

BSE India

Enclosed herewith Form C received from Mr. Paresh Bhanushali, Promoter of the Company for the disposal of Equity Shares from the market as on March 24, 2025 and March 25, 2025 respectively.

pdf